Navigation Links
New strategy to weaken traumatic memories
Date:3/17/2009

Philadelphia, PA, 17 March 2009 Imagine that you have been in combat and that you have watched your closest friend die in front of you. The memory of that event may stay with you, troubling you for the rest of your life. Posttraumatic stress disorder (PTSD) is among the most common and disabling psychiatric casualties of combat and other extremely stressful situations. People suffering from PTSD often suffer from vivid intrusive memories of their traumas. Current medications are often ineffective in controlling these symptoms and so novel treatments are needed urgently. In the February 1st issue of Biological Psychiatry, published by Elsevier, a group of basic scientists shed new light on the biology of stress effects upon memory formation. In so doing, they suggest new approaches to the treatment of the distress related to traumatic memories. Their work is based on the study of a drug, RU38486, that blocks the effects of the stress hormone cortisol.

Using an animal model of traumatic memory, investigators at the Mount Sinai School of Medicine show that treatment with RU38486 selectively reduces stress-related memories, leaving other memories unchanged. They also found that the effectiveness of the treatment is a function of the intensity of the initial "trauma." Although this particular study was performed in rats, their findings help to set the stage for trials in humans. Cristina Alberini, Ph.D., corresponding author on this article, explains how their findings will translate into developing clinical parameters: "First, the drug should be administered shortly before or after recalling the memory of the traumatic event. Second, one or two treatments are sufficient to maximally disrupt the memory. Third, the effect is long lasting and selective for the recalled memory. Finally, the time elapsing between the traumatic experience and the treatment seems to be an important parameter for obtaining the most efficacious treatment."


'/>"/>
Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Page: 1 2

Related medicine news :

1. AWT Management Announce Aggressive Growth and Acquisition Strategy
2. Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer
3. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
4. More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States
5. Penn Veterinary Medicine report new strategy to create genetically modified animals
6. Novel strategy under study for aggressive leukemia
7. AIDS Action Council Commends Senator Edwards for Endorsing a National HIV/AIDS Strategy
8. Blue Shield of California Names Vincent Coppola Vice President of Strategy and Business Development
9. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
10. Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
11. Computerized training of working memory is a promising therapeutic strategy in ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2IPY follow up requires year round research on Arctic and global warming 9894 1Calixa Therapeutics to Make Multiple Presentations on CXA 101 and CXA 101 tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agent 4978 1Calixa Therapeutics to Make Multiple Presentations on CXA 101 and CXA 101 tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agent 4978 2Calixa Therapeutics to Make Multiple Presentations on CXA 101 and CXA 101 tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agent 4978 3Calixa Therapeutics to Make Multiple Presentations on CXA 101 and CXA 101 tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agent 4978 4Schofield Media Names Brian Reshefsky Group President 56972 1